The European Medicines Agency (EMA), headquartered in the Netherlands, plays a pivotal role in the regulation and oversight of medicinal products across Europe. Established in 1995, the agency has been instrumental in ensuring the safety and efficacy of medicines, contributing significantly to public health within the European Union and beyond.
Operating primarily within the medical, precision and optical instruments sector, the EMA focuses on the evaluation and supervision of pharmaceuticals, fostering innovation while maintaining rigorous safety standards. Its core services include scientific assessments, regulatory guidance, and post-marketing surveillance, which are essential for maintaining high-quality healthcare.
Recognised for its commitment to transparency and collaboration, the EMA has achieved notable milestones, including the rapid approval of COVID-19 vaccines, showcasing its agility in responding to public health emergencies. As a leading authority in the pharmaceutical landscape, the EMA continues to shape the future of medicine in Europe.
-7 vs industry average
European Medicines Agency’s score of 20 is lower than 40% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at European Medicines Agency?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Medical Device Manufacturing has typical carbon intensity
Industry performance
The Medical Device Manufacturing industry has reduced its overall emissions by 18% since 2019
Emissions trajectory 2020 – 2026
Reported emissions
Scope 3 accounts for ••• of total emissions.
European Medicines Agency's reported carbon emissions
The European Medicines Agency (EMA), headquartered in the Netherlands and operating within the medical, precision and optical instruments, watches and clocks industry (33), has reported Scope 3 emissions primarily from business travel. For 2023, the EMA's total reported emissions were approximately 1,901,900 kg CO2e, with business travel accounting for approximately 1,682,900 kg CO2e. This represents a significant increase from previous years, with 2022 emissions at approximately 979,900 kg CO2e (business travel: 791,600 kg CO2e) and 2020 emissions at approximately 809,100 kg CO2e (business travel: 525,700 kg CO2e). In 2021, emissions were approximately 178,500 kg CO2e, with business travel at approximately 800 kg CO2e. The EMA has disclosed Scope 3 emissions data for business travel for the years 2020 through 2023. Data for Scope 1 and Scope 2 emissions are not available. The organization has not published specific greenhouse gas reduction targets or commitments in the provided information. Further details on purchased goods and services within Scope 3 emissions are also noted as missing data points.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
European Medicines Agency’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for European Medicines Agency yet.
Scope 3 top emissions categories
1 of 15 categories disclosedSee all scope 3 categories
Already have an account? Sign in now
Emissions comparison with industry peers
View similar organisations
European Medicines Agency
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project